Post-Market Safety Data On Silicone-Gel Breast Implants May Prompt Labeling Changes
This article was originally published in The Gray Sheet
Executive Summary
Preliminary post-market safety data show that while silicone-gel-filled breast implants are safe, they “are not lifetime devices” and often have to be removed within 10 years, according to FDA device center Director Jeffrey Shuren.
You may also be interested in...
FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened
The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.
Study Highlights Autoimmune, CTD Issues In Women Who Had Breast Implants
Early results of a new study of 300 women who previously had breast implants, and a review of longer-term follow-up of patients who had their implants removed, found more patients have suffered autoimmune issues and connective tissue disease than have come out in FDA-mandated studies, according to the National Center for Health Research. NCHR was critical of FDA's and industry's approach to post-market surveillance of breast implants.
Breast Implant Makers Can Use Registries To Fulfill Post-Market Surveillance Duties
After years of struggling to track breast implant patients with post-market surveillance surveys, silicone gel breast implant makers will be allowed by FDA to substitute data from two new registries to fulfill their duties on post-approval studies and device tracking, an FDA epidemiologist said recently.